Robocath Begins FIH Study of Second-Generation Robotic System for Interventional Treatment of CAD

January 30, 2026—Robocath, a France-based developer of robotic solutions for interventional cardiology, announced the launch of a first-in-human (FIH) clinical study evaluating the company’s new robotic system for coronary artery disease (CAD).

The second-generation robot integrates capabilities intended to meet the increasing demands of complex coronary procedures, noted the company.

Robocath advised that the study will recruit 20 patients with CAD, primarily complex cases representative of the routine activity of a catheterization lab.

The study will be conducted at Centre Cardiologique du Nord in Saint-Denis, France, led by principal investigator Mohammed Nejjari, MD, and coinvestigator Franck Digne, MD. Additionally, Robocath’s Medical Advisory Board, including Michael Haude, MD, and Jean Fajadet, MD, will provide clinical and scientific expertise throughout the program.